Cargando…
Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic
BACKGROUND: DNA damage response (DDR) defects imply genomic instability and favor tumor progression but make the cells vulnerable to the pharmacological inhibition of the DNA repairing enzymes. Targeting cellular proteins like PARPs, which cooperate and complement molecular defects of the DDR proces...
Autores principales: | Cerrato, Aniello, Morra, Francesco, Celetti, Angela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5123312/ https://www.ncbi.nlm.nih.gov/pubmed/27884198 http://dx.doi.org/10.1186/s13046-016-0456-2 |
Ejemplares similares
-
Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation Therapy
por: Jannetti, Stephen A., et al.
Publicado: (2020) -
Potential biological role of poly (ADP-ribose) polymerase (PARP) in male gametes
por: Agarwal, Ashok, et al.
Publicado: (2009) -
Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate Cancer
por: Inderjeeth, Andrisha-Jade, et al.
Publicado: (2022) -
Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors
por: Criscuolo, Daniela, et al.
Publicado: (2019) -
Poly(ADP-Ribose) Glycohydrolase (PARG) vs. Poly(ADP-Ribose) Polymerase (PARP) – Function in Genome Maintenance and Relevance of Inhibitors for Anti-cancer Therapy
por: Harrision, Daniel, et al.
Publicado: (2020)